Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

22.2%

2 terminated/withdrawn out of 9 trials

Success Rate

33.3%

-53.2% vs industry average

Late-Stage Pipeline

11%

1 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed trials have results

Key Signals

4 recruiting1 with results

Enrollment Performance

Analytics

Phase 2

4(50.0%)

Phase 1

3(37.5%)

Phase 3

1(12.5%)

8Total

Phase 2(4)

Phase 1(3)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT05465174Phase 2Recruiting

Tovorafenib for Treatment of Craniopharyngioma in Children and Young Adults

Role: collaborator

NCT07206849Phase 2Not Yet Recruiting

Study of Tovorafenib in High-Grade Glioma and Diffuse Intrinsic Pontine Glioma (DIPG)

Role: collaborator

NCT05566795Phase 3Recruiting

DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)

Role: lead

NCT03429803Phase 1Completed

DAY101 In Gliomas and Other Tumors

Role: collaborator

NCT06752681Phase 1Recruiting

To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of DAY301 in Participants With Locally Advanced or Metastatic Solid Tumors

Role: lead

NCT04985604Phase 2Terminated

Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors

Role: lead

NCT07121829Phase 1Terminated

Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors

Role: lead

NCT04775485Phase 2Recruiting

A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors

Role: lead

NCT05760586Unknown

Expanded Access Program (EAP) for Tovorafenib (DAY101) in RAF-Altered, Relapsed or Refractory Low-Grade Glioma

Role: lead

All 9 trials loaded